Abstract
The diagnosis of ductal carcinoma in situ (DCIS) has increased dramatically following the widespread adoption of screening mammography. DCIS has a favorable prognosis overall, but is associated with an increased risk of invasive breast cancer (IBC) and occasionally, with poor outcomes. The goal of the multidisciplinary treatment of DCIS is to prevent the development of invasive disease. The identification of patients at elevated risk for progression or recurrence who require more aggressive multimodality therapy and, conversely, those who can safely forgo elements of the current therapeutic armamentarium are important current challenges.
Keywords: Ductal Carcinoma in Situ, DCIS, Controversies, Clinical Trials
Current Cancer Therapy Reviews
Title:Ductal Carcinoma In Situ: Clinical Trials Update and Resolving Controversies
Volume: 8 Issue: 3
Author(s): Robert E. Roses and Henry M. Kuerer
Affiliation:
Keywords: Ductal Carcinoma in Situ, DCIS, Controversies, Clinical Trials
Abstract: The diagnosis of ductal carcinoma in situ (DCIS) has increased dramatically following the widespread adoption of screening mammography. DCIS has a favorable prognosis overall, but is associated with an increased risk of invasive breast cancer (IBC) and occasionally, with poor outcomes. The goal of the multidisciplinary treatment of DCIS is to prevent the development of invasive disease. The identification of patients at elevated risk for progression or recurrence who require more aggressive multimodality therapy and, conversely, those who can safely forgo elements of the current therapeutic armamentarium are important current challenges.
Export Options
About this article
Cite this article as:
E. Roses Robert and M. Kuerer Henry, Ductal Carcinoma In Situ: Clinical Trials Update and Resolving Controversies, Current Cancer Therapy Reviews 2012; 8 (3) . https://dx.doi.org/10.2174/157339412802653173
DOI https://dx.doi.org/10.2174/157339412802653173 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Developments of DNA Poisons - Human DNA Topoisomerase IIα Inhibitors - as Anticancer Agents
Current Pharmaceutical Design Role of Glioma-associated GLI1 Oncogene in Carcinogenesis and Cancertargeted Therapy
Current Cancer Drug Targets Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery The Complex Dynamics of Breast Cancer
Current Women`s Health Reviews Raman Spectroscopy and Imaging: Promising Optical Diagnostic Tools in Pediatrics
Current Medicinal Chemistry Fluorescent Molecular Imaging: Technical Progress and Current Preclinical and Clinical Applications in Urogynecologic Diseases
Current Molecular Medicine Clinical Evaluation of Natural History of Peyronie’s Disease: Our Experience, Old Myths and New Certainties
Inflammation & Allergy - Drug Targets (Discontinued) Bacterial Biotransformation and Anticancer Activities of Betulin against A549, HepG2 and 5RP7 Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Genistein Affects Expression of Cytochrome P450 (CYP450) Genes in Hepatocellular Carcinoma (HEPG2/C3A) Cell Line
Drug Metabolism Letters An Instrument-Based Screening Assay for DNA-Targeted Anticancer Drugs Using Resonance Light Scattering
Combinatorial Chemistry & High Throughput Screening HER2 Targeted Therapies for Cancer and the Gastrointestinal Tract
Current Drug Targets Characterization of Solid Lipid Nanoparticles Containing Caffeic Acid and Determination of its Effects on MCF-7 Cells
Recent Patents on Anti-Cancer Drug Discovery The Microarray Gene Profiling Analysis of Glioblastoma Cancer Cells Reveals Genes Affected by FAK Inhibitor Y15 and Combination of Y15 and Temozolomide
Anti-Cancer Agents in Medicinal Chemistry Annexins Bend Wound Edges during Plasma Membrane Repair
Current Medicinal Chemistry Drug Delivery Systems Based on Polymeric Micelles and Ultrasound: A Review
Current Pharmaceutical Design Immobilized OBOC Combinatorial Bead Array to Facilitate Multiplicative Screening
Combinatorial Chemistry & High Throughput Screening Advancement in Obesity Management: Leptin and Adiponectin Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Antihistamines: Past Answers and Present Questions
Current Drug Safety Tumorspheres Derived from HCC Cells are Enriched with Cancer Stem Cell-like Cells and Present High Chemoresistance Dependent on the Akt Pathway
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Medicinal Chemistry of Sulfonamides. Rational Design as Anti-Tumoral, Anti-Bacterial and Anti-Inflammatory Agents
Mini-Reviews in Medicinal Chemistry